Cai Yingke, Yao Yuxuan, Dong Yi, Wang Dang, Luo Jing, Heng Gang
Department of Hepatopancreatobiliary, Hernia and Vascular Surgery, Caidian District People's Hospital of Wuhan, Wuhan, China.
Department of General Surgery, People's Liberation Army of China (PLA) Middle Military Command General Hospital, Wuhan, China.
Front Oncol. 2025 Jun 6;15:1504604. doi: 10.3389/fonc.2025.1504604. eCollection 2025.
Percutaneous transhepatic biliary drainage (PTBD) was widely used for bile drainage in hilar cholangiocarcinoma (HCCA) patients, due to its exact effectiveness in relieving obstructive jaundice. However, the potential association between PTBD and increased local tumor spread (including portal vein invasion and lymph node metastasis) remained unclear, as this procedure might prolong the waiting time and lead to potential risks of portal vein injury. This study aimed to investigate whether HCCA patients undergoing PTBD exhibit higher risks of portal vein invasion and lymph node metastasis after radical resection.
The clinical data of 341 HCCA patients was retrospectively analyzed. PTBD was exclusively used as the preoperative biliary drainage method, excluding patients who underwent endoscopic nasobiliary drainage or endoscopic biliary stenting. Portal vein invasion and lymph node metastasis were verified by postoperative pathological examinations.
In this study, 163 patients (47.8%) received preoperative PTBD. These patients experienced significantly higher risks of portal vein invasion [odds ratio (OR): 1.86, p = 0.027] and lymph node metastasis (OR: 1.94, p = 0.008) compared to those 178 patients (52.2%) in the non-PTBD group. The Kaplan-Meier survival analysis revealed significantly better OS (p = 0.039) in the non-PTBD group. Causal mediation analysis revealed that the effect of PTBD on survival was partly mediated by portal vein invasion and lymph node metastasis. Additionally, the length of hospitalization in PTBD group was obviously longer (26.7 days vs. 21.8 days, p = 0.002).
Preoperative PTBD was associated with increased incidence of portal vein invasion and lymph node metastasis in HCCA patients accepting R0 resection.
经皮肝穿刺胆道引流术(PTBD)因其在缓解肝门部胆管癌(HCCA)患者梗阻性黄疸方面的确切疗效,被广泛用于胆汁引流。然而,PTBD与局部肿瘤扩散增加(包括门静脉侵犯和淋巴结转移)之间的潜在关联仍不明确,因为该操作可能会延长等待时间并导致门静脉损伤的潜在风险。本研究旨在调查接受PTBD的HCCA患者在根治性切除术后是否具有更高的门静脉侵犯和淋巴结转移风险。
回顾性分析341例HCCA患者的临床资料。PTBD被专门用作术前胆道引流方法,排除接受内镜鼻胆管引流或内镜胆道支架置入术的患者。门静脉侵犯和淋巴结转移通过术后病理检查证实。
在本研究中,163例患者(47.8%)接受了术前PTBD。与非PTBD组的178例患者(52.2%)相比,这些患者发生门静脉侵犯[比值比(OR):1.86,p = 0.027]和淋巴结转移(OR:1.94,p = 0.008)的风险显著更高。Kaplan-Meier生存分析显示,非PTBD组的总生存期显著更好(p = 0.039)。因果中介分析显示,PTBD对生存的影响部分由门静脉侵犯和淋巴结转移介导。此外,PTBD组的住院时间明显更长(26.7天对21.8天,p = 0.002)。
术前PTBD与接受R0切除的HCCA患者门静脉侵犯和淋巴结转移发生率增加有关。